Michael Blaiss, AAAAI 2022: An Analysis of Gefapixant in Chronic Cough
touchRESPIRATORY caught up with Dr. Michael S. Blaiss (Medical College of Georgia, Augusta University, Augusta, GA, USA) to discuss his analysis of phase 3 trials of gefapixant in chronic cough.
The abstract ‘Comparisons Of Baseline Characteristics And Treatment Efficacy In Individuals With Refractory Or Unexplained Chronic Cough Enrolled In Phase 3 Trials Of Gefapixant‘ was presented at AAAAI 2022, 25-28 February.
- What have the COUGH-1 and COUGH-2 studies taught us about the efficacy and safety of gefapixant in patients with RCC or UCC? (0:20)
- What were the aims of the current comparison of baseline characteristics and treatment efficacy in patients in these two studies? (1:49)
- What questions remain unanswered? (3:22)
Disclosures: Michael Blaiss discloses consulting for Merck and Bellus, serving on advisory boards for Merck and Bellus, and participating in Speaker’s Bureaus for Merck.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the AAAAI meeting 2022
Share this Video
Related Videos In Chronic Cough
Alan Kaplan: The IPCRG Sentinel Network and Respiratory Q&A
We were delighted to meet with Prof. Alan Kaplan (University of Toronto, Toronto, ON, Canada) to discuss the international IPCRG Sentinel Network which represents each continent and includes over 100 primary care clinicians. The IPCRG is providing answers based on published peer reviewed evidence to COVID and respiratory questions from the Sentinel Network. Questions Could […]
James Wingfield Digby, ERS 2022: Hypotonic Saline in the Diagnosis of Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population; however chronic cough is often unrecognized, underdiagnosed and there remain many unmet needs in its treatment. It was a pleasure to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around his study […]
James Wingfield Digby, ERS 2022: Low-dose Opiates for Refractory/Unexplained Chronic Cough
Chronic cough is a persistent cough lasting ≥8 weeks and is estimated to affect between 2-18% of the global population. touchRESPIRATORY were delighted to speak with Dr. James Wingfield Digby (University of Manchester, Manchester, UK) around the aims and design of the real world study investigating low-dose opiates in the treatment of chronic cough and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!